Abstract:Heterogeneity of neurodegenerative diseases, including Alzheimer’s disease (AD), has hampered precision diagnosis and prognosis. Machine learning methods are able to dissect neuroanatomical heterogeneity and enable identification of disease subtypes via their imaging signatures. We apply a novel semi‐supervised deep‐learning clustering method to derive dimensions of neurodegeneration, and investigate longitudinal paths in this dimensional system. Analyses used structural MRIs (from the Alzheimer’s Disease Neuroimaging Initiative and the Baltimore Longitudinal Study of Aging; total 2,832 participants; 8,146 scans) including controls and patients with Mild Cognitive Impairment (MCI) and AD. Smile‐GAN identified 4 neurodegenerative patterns/axes (Figure 1): P1, normal anatomy; P2, mild/diffuse atrophy; P3, focal medial temporal atrophy; P4, advanced neurodegeneration. Further application to longitudinal data revealed two distinct progression pathways: P1→P2→P4 and P1→P3→P4. Clinically, P2 participants showed worse performance in executive function than P3 participants (median ADNI‐EF= ‐0.29 vs. ‐0.1, with p=0.038) but had better memory (ADNI‐MEM= ‐0.13 vs. ‐0.39, with p=0.003) (Figure 2). Progression to P4 occurred more rapidly from P3 than P2, with median survival time to progression of 4.5 years and 3.2 years for P2 and P3 MCI/Dementia participants, respectively. Baseline expression of these patterns predicted the pathway and rate of future neurodegeneration, with high accuracy for determining whether P1 participants would progress and whether they would progress to P2 or P3 (Cox‐proportional‐hazard model average concordance index (CI) on the validation set of 0.8±0.02). Pattern expression offered better performance (CI=0.72±0.02) in predicting clinical conversion from MCI to Dementia compared to amyloid/tau (CI=0.69±0.02), with all three together showing modest improvement over pattern performance (CI=0.76±0.02). A composite risk score comprised of pattern probabilities, Abeta, pTau, presence of APOE E4, and ADAS‐cog score was able to predict survival time with an average concordance index, 0.78±0.02 on randomly split validation sets. (Figure 3). Four reproducible volumetric patterns, and 2 major longitudinal pathways were revealed using deep learning, which can be determined on an individual patient basis and has implications for rate of future decline. These pattern‐based biomarkers can enrich the N‐dimension of the A/T/N framework which may inform on clinical trial enrollment and monitoring outcomes in a more personalized manner.

Detecting biological heterogeneity patterns in ADNI amnestic mild cognitive impairment based on volumetric MRI

Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study

Alteration of Regional Homogeneity and White Matter Hyperintensities in Amnestic Mild Cognitive Impairment Subtypes Are Related to Cognition and CSF Biomarkers

Disentangling the heterogeneity of brain atrophy in Alzheimer’s Disease

Differentiating Between Healthy Control Participants and Those with Mild Cognitive Impairment Using Volumetric MRI Data

Longitudinal Structural MRI Analysis and Classification in Alzheimer's Disease and Mild Cognitive Impairment.

P-020: Regional Gray Matter Reductions in Alzheimer’s Dementia and Amnestic Mild Cognitive Impairment: Preliminary Findings from the Alzheimer’s Disease Neuroimaging Initiative Using Voxel-Based Morphometry

Data‐driven approach reveals heterogeneity and region‐specific association of white matter hyperintensities with the APOE genotype

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment

Voxel-based Morphometry of Amnestic Mild Cognitive Impairment and Alzheimer's Disease

Grey-matter volume as a potential feature for the classification of Alzheimer’s disease and mild cognitive impairment: an exploratory study

Analysis of Regional MRI Volumes and Thicknesses As Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease

Disentangling brain heterogeneity via semi‐supervised deep‐learning and MRI: Application to dimensional representations of Alzheimer’s disease

P3‐060: Voxel‐based Morphometry of Amnestic Mild Cognitive Impairment and Alzheimer's Disease

Volume Changes of Hippocampal and Amygdala Subfields in Patients with Mild Cognitive Impairment and Alzheimer’s Disease

MRI‐guided Clustering of Alzheimer’s Disease patients: A post‐hoc analysis of Phase 3 Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer’s Disease

Classifying MCI Subtypes in Community-Dwelling Elderly Using Cross-Sectional and Longitudinal MRI-Based Biomarkers.

Classification of Alzheimer’s disease progression based on sMRI using gray matter volume and lateralization index

Automated Brain MRI Volumetry Differentiates Early Stages of Alzheimer’s Disease From Normal Aging

IC–P–025: Regional Network Pattern of MRI Gray Matter Volume in Alzheimer's Dementia